natgillin/translations-raw huggingface dataset:
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing ingenol mebutate were warranted.
Glede na podatke, predstavljene v pregledani oceni rednih posodobljenih poročil o varnosti zdravila (PSUR), odbor PRAC meni, da je sprememba informacij o zdravilu za zdravila, ki vsebujejo ingenol mebutat (ingenoli mebutas), upravičena.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing liraglutide were warranted
Odbor PRAC zato glede na podatke, predstavljene v pregledanem PSUR, meni, da so spremembe v informacijah o zdravilih, ki vsebujejo liraglutid, utemeljene.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing lomitapide were warranted.
Z upoštevanjem podatkov, predstavljenih v obravnavanem PSUR, je PRAC ocenil, da gre za utemeljene spremembe informacij o zdravilu za zdravila, ki vsebujejo lomitapid.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing mirabegron were warranted.
Zato je odbor PRAC na osnovi razpoloţljivih podatkov glede zdravil, ki vsebujejo zdravilno učinkovino mirabegron, mnenja, da so spremembe informacij o zdravilu utemeljene.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing omalizumab were warranted.
Iz navedenih razlogov in glede na vse podatke, ki so predstavljeni v pregledanem PSUR, je odbor PRAC mnenja, da so spremembe besedila v informacijah o zdravilih, ki vsebujejo omalizumab, upravičene.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing para-aminosalicylic acid were warranted.
V smislu podatkov iz pregledanega poročila PSUR je zato odbor PRAC izdal dovoljenje za spremembo podatkov o zdravilu, v katerem je para-aminosalicilna kislina.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing thalidomide were warranted.
Zato je spričo podatkov, predstavljenih v revidiranem PSUR, PRAC menil, da so spremembe informacij o zdravilu za zdravila, ki vsebujejo talidomid, upravičene.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing trametinib were warranted.
Zaradi navedenega in glede na vse razpoložljive podatke, ki so predstavljeni v pregledanem poročilu PSUR, je odbor PRAC mnenja, da so spremembe besedila v informacijah o zdravilih, ki vsebujejo trametinib, upravičene.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considers that changes to the product information of medicinal products containing umeclidinium bromide /vilanterol are warranted.
PRAC zato glede na podatke, predstavljene v pregledanem PSUR/pregledanih PSUR, meni, da so spremembe v informacijah o zdravilih, ki vsebujejo umeklidinijev bromid/vilanterol, utemeljene.
Therefore, in view of the data presented in the reviewed PSURs, the PRAC considered that changes to the product information of medicinal products containing aripiprazole were warranted.
Zato glede na podatke, predstavljene v obravnavani oceni PSUR, odbor PRAC meni, da so spremembe informacij o zdravilih, ki vsebujejo aripiprazol, utemeljene.
Therefore, in view of the data presented in the reviewed PSURs, the PRAC considered that changes to the product information of medicinal products containing pregabalin were warranted.
Odbor PRAC zato skladno s podatki v pregledanih poročilih PSUR meni, da je potrebna posodobitev informacij o zdravilih, ki vsebujejo pregabalin.
Therefore, in view of the data presented in the reviewed PSURs, the PRAC considered that changes to the product information of medicinal products containing sevelamer hydrochloride and carbonate were warranted.
Glede na podatke, predstavljene v pregledanih PSUR, odbor PRAC zato meni, da so utemeljene spremembe informacij o zdravilih, ki vsebujejo sevelamerijev klorid in karbonat.
Therefore, in view of the data presented in the reviewed PSURs, the PRAC considered that changes to the product information of medicinal products containing sevelamer hydrochloride and carbonate were warranted.
Glede na podatke, predstavljene v pregledanih PSUR,odbor PRAC zato meni, da so utemeljene spremembe informacij o zdravilih, ki vsebujejo sevelamerijev klorid in karbonat.
Therefore, information on pulmonary hypertension is included in sections 4.4 and 4.8 of the thalidomide product information.
Zato so informacije o pljučni hipertenziji vključene v poglavjih 4.4 in 4.8 SmPC za talidomid.
Therefore, information regarding drug- drug interactions with other antiretroviral products (including protease inhibitors and non-nucleoside reverse transcriptase inhibitors) is not provided (see section 4.4).
Zato informacije o medsebojnem delovanju z drugimi protiretrovirusnimi zdravili (vključno z zaviralci proteaze in nenukleozidnimi zaviralci reverzne transkriptaze) niso na voljo (glejte poglavje 4.4).
Therefore, information regarding drug-drug interactions with other antiretroviral products (including PIs and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) is not provided (see section 4.4).
Zato informacije o medsebojnem delovanju z drugimi protiretrovirusnimi zdravili (vključno s PI in nenukleozidnimi zaviralci reverzne transkriptaze [non-nucleoside reverse transcriptase inhibitors, NNRTI]) niso navedene (glejte poglavje 4.4).
Therefore, inhibitors of these isoenzymes reduce vardenafil clearance.
Zaviralci teh izoencimov lahko zato zmanjšajo očistek vardenafila.
Therefore, inhibitors of these metabolic pathways are not expected to affect the elimination of temsirolimus.
Zato ne pričakujemo, da bi zaviralci teh presnovnih poti vplivali na odstranjevanje temsirolimusa iz telesa.
Therefore, interactions between melatonin and other active substances as a consequence of melatonin’s effect on CYP1A enzymes are not likely to be significant.
Zato je manj verjetno, da so interakcije med melatoninom in drugimi zdravilnimi učinkovinami, kot posledica učinkovanja melatonina na CYP1A encime, pomembne.
Therefore, interactions resulting from displacement of highly protein- bound drugs are unlikely.
Zato interakcije, ki se kažejo kot izrivanje zdravil pretežno vezanih na beljakovine, niso verjetne.
Therefore, interactions resulting from displacement of highly protein-bound drugs are unlikely.
Zato interakcije, ki bi bile posledica izrivanja zdravil, pretežno vezanih na beljakovine, niso verjetne.
Therefore, interactions with other medicinal products affecting plasma protein binding or elimination by biotransformation are unlikely.
Interakcije z drugimi zdravili, ki bi vplivale na vezavo na plazemske beljakovine ali na izločanje z biotransformacijo, so zato malo verjetne.
Therefore, Intrinsa should not be used in women on concomitant CEE (see sections 4.2 and 5.1).
Zato zdravila Intrinsa ne smejo uporabljati ženske, ki sočasno prejemajo CEE (glejte poglavji 4.2 in 5.1).
Therefore, ISENTRESS should be used with caution in patients with severe hepatic impairment (see sections 4.2 and 5.2).
Pri bolnikih s hudo okvaro jeter je zato treba zdravilo ISENTRESS uporabljati previdno (glejte poglavji 4.2 in 5.2).
Therefore, it is important that you continue taking Aptivus correctly, as described above.
Zato je pomembno, da nadaljujete z jemanjem zdravila Aptivus pravilno, kot je opisano v teh navodilih.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or shortly following treatment.
Zato je treba razmisliti o tej diagnozi pri bolnikih, ki imajo diarejo med zdravljenjem ali tik po njem.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of Doribax (see section 4.8).
Po jakosti je lahko blag do smrtno nevaren, zato je pomembno, da upoštevate to diagnozo pri bolnikih, ki dobijo drisko med ali po prejemanju zdravila Doribax (glejte poglavje 4.8).
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the treatment with dalbavancin (see section 4.8).
Zato je pri pacientih z drisko med ali po zdravljenju z dalbavancinom pomembno upoštevati tudi to diagnozo (glejte poglavje 4.8).
Therefore, it is not recommended to administer eptifibatide in patients who have previously experienced immune mediated thrombocytopenia with GP IIb/IIIa inhibitors, including eptifibatide.
Zato eptifibatida ni priporočljivo uporabiti pri bolnikih, ki so predhodno imeli imunsko trombocitopenijo med uporabo zaviralcev GP IIb/IIIa, vključno z eptifibatidom.
Therefore, it is not recommended to concomitantly ingest aluminium-based antacids and deferiprone.
Zato ni priporočljivo sočasno jemanje antacidov,ki vsebujejo aluminijeve spojine in deferiprona.
Therefore, it is not recommended to drink alcohol during treatment.
Med zdravljenjem z zdravilom Leflunomid Teva zato ni priporočljivo pitje alkohola.
Therefore, it is recommended that if nitisinone treatment with Orfadin hard capsules is initiated with food, this should be maintained on a routine basis, see section 4.2.
Če se zdravljenje z nitizinonom z zdravilom Orfadin trde kapsule začne ob hrani, se priporoča, da se to vzdržuje rutinsko, glejte poglavje 4.2.
Therefore, it is recommended that the MA is subjected to an additional renewal.
Zato se priporoča, da je dovoljenje za promet predmet dodatnega podaljšanja.
Therefore, it is recommended that the platelet counts be measured before the initiation of therapy with enoxaparin sodium and then regularly thereafter during the treatment.
Zato je priporočljivo, da število trombocitov izmerite pred uvedbo zdravljenja z natrijevim enoksaparinatom in nato v rednih intervalih ves čas zdravljenja.
Therefore, it is recommended that the tablets should be taken after an overnight fast (minimum 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see section 4.2).
Zato je priporočljivo, da bolnik vzame tablete po postu prek noči (post naj traja najmanj 6 ur), po vzetem odmerku pa mora miniti vsaj 30 minut, preden bolnik zaužije pijačo ali hrano (glejte poglavje 4.2).
Therefore, it is recommended that the tablets should be taken after an overnight fast (minimum 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see section 4.2).
Zato se priporoča, da bolnik vzame tablete po nočnem postu (post naj traja najmanj 6 ur), po vzetem odmerku pa mora miniti še vsaj 30 minut, preden bolnik zaužije pijačo ali hrano (glejte poglavje 4.2).
Therefore, it is recommended that you use an additional safe and effective contraceptive method when taking Inovelon.
Zato vam med jemanjem zdravila Inovelon priporočamo uporabo dodatnih varnih in učinkovitih kontracepcijskih metod.
Therefore, it is recommended that you use other forms of safe and effective contraception, when taking Zebinix up to the end of the current menstrual cycle after stopping treatment.
Zato je med jemanjem zdravila Zebinix in do konca trenutnega menstrualnega cikla po končanem zdravljenju priporočeno uporabljati drugo obliko varne in učinkovite kontracepcije.
Therefore, it is recommended to administer strong P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) using staggered dosing, preferably 6 hours or 12 hours apart from GIOTRIF (see section 4.2).
Zatorej je priporočljivo močne zaviralce P-gp (tudi, toda ne samo, ritonavir, ciklosporin A, ketokonazol, itrakonazol, eritromicin, verapamil, kinidin, takrolimus, nelfinavir, sakvinavir in amiodaron) dajati z zamikom, najbolje z razmikom 6 ali 12 ur od jemanja zdravila GIOTRIF (glejte poglavje 4.2).
Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.
Zato je po zamenjavi katerega koli zdravila bolnike priporočljivo skrbno spremljati glede nastanka inhibitorjev.
Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.
Zato je vse bolnike priporočljivo spremljati glede pojava zaviralcev po vsaki zamenjavi zdravila.
Therefore, it is recommended to monitor patients carefully for inhibitor occurrence following any product switch.
Zato se po kakršnikoli zamenjavi zdravila priporoča skrbno spremljanje vseh bolnikov glede nastanka zaviralcev.
Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings.
Za uničevanje bolh v okolici priporočamo dodatno uporabo primernega sredstva za zatiranje bolh in njihovih ličink v okolici.
Therefore, it may be necessary to combine Advocate treatment with treatments aimed at breaking the flea life cycle in the surroundings.
Za uničevanje bolh v okolici priporočamo dodatno uporabo primernega sredstva za zatiranje bolh in njihovih ličink v okolici.
Therefore, it may occur that MACI cannot be delivered.
Zato se lahko zgodi, da zdravila MACI ne bo mogoče uporabiti.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl- transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
Zdravila CellCept zato ne dajemo bolnikom z redkim dednim pomanjkanjem hipoksantin-gvanin-fosforibozil-transferaze (HGPRT), kot sta Lesch-Nyhlanov in Kelley-Seegmillerjev sindrom.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl- transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
Zdravila Myfenax zato ne dajemo bolnikom z redkim dednim pomanjkanjem hipoksantin-gvanin-fosforiboziltransferaze (HGPRT), kot sta Lesch-Nyhlanov in Kelley-Seegmillerjev sindrom.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
Zdravila Mofetilmikofenolat Teva zato ne dajemo bolnikom z redkim dednim pomanjkanjem hipoksantin-gvanin- fosforiboziltransferaze (HGPRT), kot sta Lesch-Nyhlanov in Kelley-Seegmillerjev sindrom.
Therefore, it should not be used in patients with baseline haemoglobin > 13 g/dl.
Zato se zdravila pri bolnikih z izhodiščno koncentracijo hemoglobina > 13 g/dl ne sme uporabljati.
Therefore, its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment.
RF sevanja so zato majhna in ni verjetno, da bi povzročila moteče signale elektronske opreme, nameščene v bližini.
Therefore, its use in paediatric patients is not recommended due to a lack of data on safety and efficacy.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti, uporaba zdravila pri pediatričnih bolnikih ni priporočljiva.
Therefore, Jentadueto must be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further (see section 4.4).
Zato je treba zdravilo Jentadueto ukiniti pred ali med študijo, ponovno pa ga smemo uvesti šele po 48 urah in ponovni oceni ledvičnega delovanja, če se to ni dodatno poslabšalo (glejte poglavje 4.4).
Therefore, Kaletra can be started safely 2 weeks after cessation of St John's wort.
Zato je zdravilo Kaletra mogoče varno začeti uporabljati 2 tedna po prenehanju jemanja šentjanževke.
Therefore, Kaletra tablets may be taken with or without food.
Tablete Kaletra lahko torej bolnik vzame s hrano ali brez nje.
Therefore, keep injection syringes and needles as well.
Zato imejte vedno na zalogi tudi brizge in igle.
Therefore, keep injection syringes and needles as well.
Zato imejte vedno na zalogi tudi injekcijske brizge in igle.
Therefore, known strong (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, boceprevir, telaprevir) or moderate (e.g. erythromycin, diltiazem, fluconazole, verapamil) inhibitors of this isozyme are not recommended with olaparib (see section 4.4).
Zato sočasna uporaba olapariba z znanimi močnimi zaviralci (npr. s itrakonazolom, telitromicinom, klaritromicinom, zaviralcem proteaz okrepljenim z ritonavirjem ali kobicistatom, boceprevirjem, telaprevirjem) ali zmernimi zaviralci (npr. z eritromicinom, diltiazemom, flukonazolom, verapamilom) tega izoencima ni priporočljiva (glejte poglavje 4.4).
Therefore, known strong inducers of this isozyme (e.g. phenytoin, rifampicin, rifapentine, carbamazepine, nevirapine, phenobarbital, and St John’s Wort) are not recommended with olaparib, as it is possible that the efficacy of olaparib could be substantially reduced (see section 4.4).
Zato olapariba ni priporočljivo uporabljati z znanimi močnimi induktorji tega izoencima (npr. s fenitoinom, rifampicinom, rifapentinom, karbamazepinom, nevirapinom, fenobarbitalom in šentjanževko), ker obstaja možnost, da se učinkovitost olapariba bistveno zmanjša (glejte poglavje 4.4).
Therefore, Levodopa/Carbidopa/Entacapone Orion and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Zato je treba pri jemanju zdravila Levodopa/Carbidopa/Entacapone Orion in železovih pripravkov upoštevati najmanj 2-3 urni razmak med obema zdraviloma (glejte poglavje 4.8).
Therefore, live vaccines should not be given concurrently with Ilaris unless the benefits clearly outweigh the risks.
Iz tega razloga v času zdravljenja z zdravilom Ilaris bolniki ne smejo biti cepljeni z živimi cepivi, razen če koristi nedvomno odtehtajo tveganja.
Therefore, live vaccines should not be given concurrently with Kineret.
Živih cepiv zato ne smete uporabljati sočasno z zdravilom Kineret.
Therefore, Livensa should not be used in women on concomitant CEE (see sections 4.2 and 5.1).
Zato zdravila Livensa ne smejo uporabljati ženske, ki sočasno prejemajo CEE (glejte poglavji 4.2 in 5.1).
Therefore, long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects.
Dolgotrajna kumulativna izpostavljenost sevanju je lahko povezana z večjim tveganjem za raka in prirojene okvare.
Therefore, LUMIGAN should be used with caution in patients with known risk factors for macular oedema (e.g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).
Zato je treba pri bolnikih z znanimi dejavniki tveganja za makularne edeme (n.pr. bolniki z afakijo, bolniki s psevdoafakijo s poškodovano posteriorno lečno kapsulo) zdravilo LUMIGAN uporabljati previdno.
Therefore, Lutetium metal- ion toxicity of EndolucinBeta (177Lu)-labelled medicinal products can be excluded.
Zato je mogoče toksičnost kovinskih ionov lutecija pri zdravilih, označenih z radionuklidnim predhodnikom EndolucinBeta (177Lu), izključiti.
Therefore, Lynparza is not recommended for use in patients with hepatic impairment (serum bilirubin greater than 1.5 times upper limit of normal), as safety and efficacy have not been established.
Zato zdravila Lynparza ni priporočljivo uporabljati pri bolnicah z okvaro jeter (bilirubin v serumu več kot 1,5-kratna zgornja normalna meja), ker varnost in učinkovitost nista ugotovljeni.
Therefore, M4 accounts for approximately 4% of total pharmacologic activity.
Zato M4 prispeva približno 4 % k celotnemu farmakološkemu delovanju.
Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTIs are available.
Nadaljevanje zdravljenja z lamivudinom kljub mutaciji M184V pride v poštev samo v primerih, ko drugih učinkovitih NRTI ni na voljo.
Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTIs are available.
Nadaljevanje zdravljenja z lamivudinom kljub pojavu mutacije M184V pride v poštev samo v primerih, ko drugih učinkovitih NRTI ni na voljo.
Therefore, maintaining lamivudine therapy despite emergence of M184V mutation should only be considered in cases where no other active NRTI’s are available.
Nadaljevanje zdravljenja z lamivudinom kljub mutaciji M184V pride v poštev samo v primerih, ko drugih učinkovitih NRTI ni na voljo.
Therefore, maraviroc can be taken with or without food at the recommended doses (see section 4.2).
Zato je mogoče maravirok v priporočenih odmerkih jemati s hrano ali brez nje (glejte poglavje 4.2).
Therefore, medicinal products metabolised by CYP1A2 (such as duloxetin, alosetron, theophylline and tizanidine) should be used with caution during treatment with teriflunomide, as it could lead to the reduction of the efficacy of these products.
Zato je treba zdravila, ki se presnavljajo s CYP1A2 (kot so duloksetin, alosetron, teofilin in tizanidin), med zdravljenjem s teriflunomidom uporabljati previdno, saj lahko sočasna uporaba privede do zmanjšanja učinkovitosti navedenih zdravil.
Therefore, medicinal products metabolised by CYP1A2 (such as duloxetine, alosetron, theophylline and tizanidine) should be used with caution during treatment, as it could lead to the reduction ofthe efficacy of these products.
Zato je treba med zdravljenjem previdno uporabljati zdravila, ki se presnavljajo s CYP1A2 (npr. duloksetin, alosetron, teofilin in tizanidin), ker lahko zmanjša učinkovitost teh zdravil.
Therefore, medicinal products that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine, amantadine mexiletine, zidovudine, cisplatin, quinine, and procainamide may interact with pramipexole resulting in reduced clearance of pramipexole.
Zdravila, ki zavirajo to aktivno pot izločanja skozi ledvice ali se izločajo preko nje, na primer cimetidin, amantadin, meksiletin, zidovudin, cisplatin, kinin in prokainamid lahko torej medsebojno delujejo s pramipeksolom tako, da se zmanjša ledvični očistek pramipeksola.
Therefore, medicinal products that either share this metabolic pathway or modify CYP3A4 activity may modify the pharmacokinetics of amprenavir.
Tako lahko zdravila, ki bodisi z njima delijo to presnovno pot bodisi spremenijo aktivnost CYP3A4, spremenijo farmakokinetične lastnosti amprenavirja.
Therefore, men being treated with docetaxel are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment.
Med zdravljenjem morata in moški in ženska uporabljati kontracepcijsko zaščito, moški pa jo mora mora uporabljati še vsaj šest mesece po zdravljanja.
Therefore, men being treated with it should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment. because of the possibility of irreversible infertility due to therapy with TMZ.
Zaradi tega je treba moškim, ki se zdravijo s TMZ, svetovati naj ne spočnejo otroka še 6 mesecev po zadnjem odmerku in naj se pred zdravljenjem posvetujejo glede kriokonzervacije sperme, zaradi možnost ireverzibilne neplodnosti po zdravljenju s TMZ.
Therefore, MEPACT should not be used during pregnancy and in women not using effective contraception.
Zdravilo MEPACT se zato ne sme uporabljati med nosečnostjo in pri ženskah, ki ne uporabljajo učinkovite kontracepcije.
Therefore, monitoring of temperature and measures to lower the fever (such as antipyretic medication as seems clinically necessary) are recommended in young children (e.g. up to approximately 6 years of age) after each dose of Pandemrix.
Zato je mlajšim otrokom (npr. do približno 6. leta starosti) po vsakem odmerku cepiva Pandemrix priporočljivo kontrolirati telesno temperaturo in uporabiti ukrepe za znižanje zvišane telesne temperature (npr. antipiretična zdravila, če se zdi klinično potrebno).